Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2019 | Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition

Mary Ann Anderson • 20 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia

Mary Ann Anderson, MBBS, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, discusses the development of resistance to BCL-2 receptor inhibition, and what it means for treatment strategies. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Mary Ann Anderson

2:32
Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL
Mary Ann Anderson • 8 Sep 2023
0:49
VENICE II trial: health-related QoL in patients with CLL treated with venetoclax
Mary Ann Anderson • 8 Sep 2023
2:30
Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies
Mary Ann Anderson • 8 Sep 2023
0:59
iwCLL 2019 - facilitating the development of novel agents and treatment outcomes
Mary Ann Anderson • 21 Sep 2019

Related Videos

5:27
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
2:12
AlloSCT for AML with MDS-related features as per the ICC and WHO 2022 classifications
Arnon Nagler • 16 Apr 2024
2:02
Relapse incidence post-alloSCT with PTCy for AML in CR1
Arnon Nagler • 16 Apr 2024
1:35
Outcomes of alloSCT following blinatumomab in children and young adults with R/R B-ALL
Mattia Algeri • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals